SG10201606063RA - Neuroactive steroid formulations and methods of treating cns disorders - Google Patents
Neuroactive steroid formulations and methods of treating cns disordersInfo
- Publication number
- SG10201606063RA SG10201606063RA SG10201606063RA SG10201606063RA SG10201606063RA SG 10201606063R A SG10201606063R A SG 10201606063RA SG 10201606063R A SG10201606063R A SG 10201606063RA SG 10201606063R A SG10201606063R A SG 10201606063RA SG 10201606063R A SG10201606063R A SG 10201606063RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- cns disorders
- neuroactive steroid
- treating cns
- steroid formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589740P | 2012-01-23 | 2012-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201606063RA true SG10201606063RA (en) | 2016-09-29 |
Family
ID=48874058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606063RA SG10201606063RA (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
| SG11201503882SA SG11201503882SA (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503882SA SG11201503882SA (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20150018327A1 (en) |
| EP (3) | EP3650027A1 (en) |
| JP (5) | JP2015513316A (en) |
| CN (2) | CN112472814A (en) |
| AU (3) | AU2013212287B2 (en) |
| BR (1) | BR112014018110B1 (en) |
| CA (1) | CA2862076C (en) |
| CY (1) | CY1122527T1 (en) |
| DK (1) | DK2806877T3 (en) |
| ES (1) | ES2758446T3 (en) |
| HK (1) | HK1204281A1 (en) |
| HR (1) | HRP20192348T1 (en) |
| HU (1) | HUE046800T2 (en) |
| IL (4) | IL298436B1 (en) |
| LT (1) | LT2806877T (en) |
| MX (3) | MX2014008895A (en) |
| NZ (2) | NZ773177A (en) |
| PL (1) | PL2806877T3 (en) |
| PT (1) | PT2806877T (en) |
| RS (1) | RS59734B1 (en) |
| RU (2) | RU2681835C2 (en) |
| SG (2) | SG10201606063RA (en) |
| SI (1) | SI2806877T1 (en) |
| WO (1) | WO2013112605A2 (en) |
| ZA (1) | ZA201405401B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006318349B2 (en) | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| MX2014008895A (en) | 2012-01-23 | 2014-11-25 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders. |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| WO2014071449A1 (en) * | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP4335505A3 (en) * | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| TW202235090A (en) | 2014-10-16 | 2022-09-16 | 美商賽吉醫療公司 | Compositions and methods for treating cns disorders |
| PL3224269T3 (en) | 2014-11-27 | 2020-08-24 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US20180311258A1 (en) | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (en) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE |
| JP7114074B2 (en) | 2015-08-18 | 2022-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Amyloid binding agents including nitroxides for imaging and their therapeutic use |
| WO2017066626A1 (en) * | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
| WO2017160861A1 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah) |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| DK3481845T3 (en) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, C20 AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| US20180050107A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108148106A (en) | 2016-12-05 | 2018-06-12 | 江苏恩华络康药物研发有限公司 | A kind of water solubility allopregnenolone derivative and application thereof |
| US20210228596A1 (en) | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| EA202091144A1 (en) * | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | GANAXOLONE FOR USE IN THE TREATMENT OF HEREDITARY EPILEPTIC DISEASES |
| WO2020011789A1 (en) | 2018-07-09 | 2020-01-16 | Asarina Pharma Ab | Injectable suspensions |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| EP3946358A4 (en) * | 2019-04-05 | 2022-12-28 | The Regents of The University of California | Allopregnanolone compositions and uses thereof |
| EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| MX2022006014A (en) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating tuberous sclerosis complex. |
| WO2021195297A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| WO2023028205A1 (en) * | 2021-08-26 | 2023-03-02 | Brandeis University | Selective isonitrile inhibitors of cytochrome p450 subtypes |
| KR20240050372A (en) | 2021-09-14 | 2024-04-18 | 난징 미노바 파마슈티컬 컴퍼니, 리미티드 | Water-soluble allopregnanolone derivatives and their preparation methods and uses |
| WO2023240100A1 (en) * | 2022-06-07 | 2023-12-14 | Clarkson Clay Carew | A method to encapsulate non-polar compounds to achieve extended thermal stability and attenuate/prevent thermal and redox isomerization |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2443266A (en) * | 1944-09-02 | 1948-06-15 | Bendix Aviat Corp | Commutator brush holder |
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (en) | 1969-07-29 | 1971-01-29 | Upjohn Co | NEW 7ALPHA- AND 7BETA-METHYL-3ALPHA, 5ALPHA- CYCLOANDROSTANES AND SIMILAR 19-NOR COMPOUNDS AND THEIR PREPARATION PROCESS |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| SE8600632D0 (en) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | NOVEL PHARMACEUTICAL COMPOSITION |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| JPH06510999A (en) | 1991-09-13 | 1994-12-08 | コセンシス・インコーポレイテッド | Novel GABA↓a receptor with steroid binding site |
| US5411737A (en) | 1991-10-15 | 1995-05-02 | Merck & Co., Inc. | Slow release syneresing polymeric drug delivery device |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| BR9506779A (en) | 1994-02-14 | 1997-10-14 | Cocensys Inc | Compound pharmaceutical composition method for modulating the gaba-chloride receptor ionophore complex in an animal patient by binding to the neurosteroid site in said complex method to treat or prevent stress or anxiety in an animal patient method to relieve or prevent pms or pnd isonia in an animal patient method for treating or avoiding mood disturbances in an animal patient and method for inducing anesthesia in an animal patient |
| CA2186371A1 (en) | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| CN1171114A (en) | 1994-11-23 | 1998-01-21 | 科斯赛斯公司 | Androstane and preg nane series for allosteric modulation of gamma-amino-butyric acid receptor |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| HUP9901138A3 (en) | 1995-06-06 | 1999-11-29 | Cocensys Inc Irvine | Neuroactive steroids of the androstane and pregnane series |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DK1104760T3 (en) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoyl heteroarylpyrazole compounds as anti-inflammatory / analgesic agents |
| US6442887B2 (en) | 2000-02-25 | 2002-09-03 | Robert L. Sanquist | Live bait keeper |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| GR1003861B (en) | 2000-12-29 | 2002-04-11 | Novel gabaa modulating neurosteroids | |
| WO2002064804A2 (en) | 2001-02-13 | 2002-08-22 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP4357842B2 (en) | 2001-05-24 | 2009-11-04 | アレックザ ファーマシューティカルズ， インコーポレイテッド | Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route |
| JP2003063965A (en) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | Cilostazol aqueous composition for injection |
| CA2472184C (en) | 2002-01-14 | 2011-04-19 | David Mark Lucas | Magnetically detectable latex articles |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| EP2298316A1 (en) | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| CA2527019A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| KR20060113737A (en) * | 2003-12-22 | 2006-11-02 | 쉐링 코포레이션 | Pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EP1574222B1 (en) | 2004-03-12 | 2011-02-09 | Cipla Ltd. | Sterilization process for steroids |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| ITMI20041763A1 (en) | 2004-09-16 | 2004-12-16 | Altergon Sa | NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
| PL2261236T3 (en) | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Composition for proteasome inhibition |
| EA013433B1 (en) | 2005-02-15 | 2010-04-30 | Элан Фарма Интернэшнл Лтд. | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| PL1868614T3 (en) | 2005-03-24 | 2013-01-31 | Univ Emory | Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| US20080207601A1 (en) | 2005-04-07 | 2008-08-28 | Hythiam , Inc. | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR100784860B1 (en) | 2005-10-31 | 2007-12-14 | 삼성전자주식회사 | Nonvalitile memory device and method for fabricating the same |
| AU2006318349B2 (en) | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| KR20090064418A (en) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | Combinations containing a 4-acylaminopyridine derivative |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| KR20150080026A (en) | 2007-04-11 | 2015-07-08 | 바이오마린 파머수티컬 인크. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| US8969329B2 (en) * | 2007-06-11 | 2015-03-03 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function |
| ES2589139T3 (en) | 2007-06-15 | 2016-11-10 | Research Triangle Institute | Androstane and pregnan steroids with potent allosteric modulation properties of the GABA / ionophore chloride receptor complex |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2175886A1 (en) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| JP2011507800A (en) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | AMPA receptor antagonists for epilepsy, mental disorders, or sensory organ disorders |
| EP2224927B1 (en) | 2008-01-03 | 2014-08-20 | BioMarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| DE102008015366A1 (en) | 2008-03-20 | 2009-09-24 | Merck Patent Gmbh | Lyophilised nanoemulsion |
| WO2010063030A2 (en) | 2008-11-30 | 2010-06-03 | Feigelson, Daniel | Dermal application of vasoconstrictors |
| CZ301216B6 (en) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnane anionic compounds, process for preparing thereof and their use |
| WO2010042925A2 (en) | 2008-10-10 | 2010-04-15 | Vm Discovery Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| WO2010107922A1 (en) | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| HUE035441T2 (en) * | 2010-01-21 | 2018-05-02 | Drawbridge Pharmaceuticals Pty Ltd | Anaesthetic formulation |
| JP5832547B2 (en) | 2010-11-03 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Needle cannula containing drug |
| WO2012075286A2 (en) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| CZ303443B6 (en) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Pregnanolone derivatives substituted in position 3alpha with cationic group, process of their preparation, their use and composition containing them |
| WO2012116290A2 (en) | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| FR2973031B1 (en) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| KR20130002292A (en) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | Combination of active components inducing synergy effects of multi-targeting |
| JP2014521662A (en) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Novel 17β-heteroaryl substituted steroids as modulators of GABAA receptors |
| RU2665571C2 (en) | 2011-09-08 | 2018-08-31 | Сейдж Терапьютикс, Инк. | Neuroactive steroids, compositions and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN104136452A (en) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20140322198A1 (en) | 2011-11-29 | 2014-10-30 | Amino Up Chemical Co., Ltd. | Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
| EP2785352B1 (en) | 2011-11-29 | 2020-03-11 | Jurox Pty Ltd | Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone |
| MX2014008895A (en) | 2012-01-23 | 2014-11-25 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders. |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP4335505A3 (en) | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| JP6542127B2 (en) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | Neuroactive 19-alkoxy-17-substituted steroids, their prodrugs and methods of treatment using the same |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| CN117304245A (en) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 19-nor steroids that stimulate neural activity and methods of use thereof |
| MX362543B (en) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof. |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (en) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US20160228454A1 (en) | 2015-02-06 | 2016-08-11 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| CN108697712A (en) | 2015-10-14 | 2018-10-23 | 加利福尼亚大学董事会 | Enhance β cellular replications and/or survival |
| MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| CN110072523A (en) | 2016-09-07 | 2019-07-30 | 格利亚有限责任公司 | Symptom relevant to Neurodegenerative conditions is treated by the pharmacology cutaneous activation of cranial nerve |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
| CN110520131A (en) | 2017-04-18 | 2019-11-29 | 马瑞纳斯制药公司 | The neurosteroid preparation of sustained release injectable |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| WO2018236955A1 (en) | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
| WO2018237282A1 (en) | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| IL303083A (en) | 2017-09-14 | 2023-07-01 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EA202091144A1 (en) | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | GANAXOLONE FOR USE IN THE TREATMENT OF HEREDITARY EPILEPTIC DISEASES |
| JP2021505608A (en) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス， インコーポレイテッド | Juuterized 21- [4-cyano-pyrazole-1-yl] -19-nor-pregan-3 for treating CNS disorders. α-all-20-one derivative |
| WO2019126741A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MX2020006608A (en) | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders. |
| US11718642B2 (en) | 2018-01-12 | 2023-08-08 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP2021523938A (en) | 2018-05-04 | 2021-09-09 | アセラス ファーマシュウティカルズ コーポレーション | Neurosteroid derivatives and their use |
| TW202005653A (en) | 2018-06-12 | 2020-02-01 | 美商賽吉醫療公司 | A 19-NOR C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| AR116695A1 (en) | 2018-10-12 | 2021-06-02 | Sage Therapeutics Inc | NEUROSTEROIDS AND THEIR METHODS OF USE |
| CN113227114A (en) | 2018-10-19 | 2021-08-06 | 萨奇治疗股份有限公司 | 9(11) -unsaturated neuroactive steroids and methods of use thereof |
| JP2022510683A (en) | 2018-12-05 | 2022-01-27 | セージ セラピューティクス， インコーポレイテッド | Neurostimulatory steroids and how to use them |
| MX2021007504A (en) | 2018-12-21 | 2021-10-13 | Sage Therapeutics Inc | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof. |
| TW202110824A (en) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | Compounds, compositions, and methods of use |
| CR20210629A (en) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN114761019A (en) | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-nor C3, 3-disubstituted C21-N-pyrazolylsterols and methods of use thereof |
| CN115551874A (en) | 2020-03-18 | 2022-12-30 | 萨奇治疗股份有限公司 | Neuroactive steroids and methods of use thereof |
| WO2021195297A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2013
- 2013-01-23 MX MX2014008895A patent/MX2014008895A/en active IP Right Grant
- 2013-01-23 CA CA2862076A patent/CA2862076C/en active Active
- 2013-01-23 PT PT137407433T patent/PT2806877T/en unknown
- 2013-01-23 RU RU2014134316A patent/RU2681835C2/en active
- 2013-01-23 CN CN202011230446.5A patent/CN112472814A/en active Pending
- 2013-01-23 SG SG10201606063RA patent/SG10201606063RA/en unknown
- 2013-01-23 EP EP19195977.4A patent/EP3650027A1/en not_active Withdrawn
- 2013-01-23 NZ NZ773177A patent/NZ773177A/en unknown
- 2013-01-23 EP EP23192903.5A patent/EP4295908A3/en active Pending
- 2013-01-23 IL IL298436A patent/IL298436B1/en unknown
- 2013-01-23 SI SI201331627T patent/SI2806877T1/en unknown
- 2013-01-23 BR BR112014018110-1A patent/BR112014018110B1/en active IP Right Grant
- 2013-01-23 AU AU2013212287A patent/AU2013212287B2/en active Active
- 2013-01-23 NZ NZ627781A patent/NZ627781A/en unknown
- 2013-01-23 EP EP13740743.3A patent/EP2806877B1/en active Active
- 2013-01-23 RU RU2019104004A patent/RU2019104004A/en unknown
- 2013-01-23 CN CN201380015855.5A patent/CN104736158A/en active Pending
- 2013-01-23 JP JP2014553534A patent/JP2015513316A/en not_active Withdrawn
- 2013-01-23 RS RS20191698A patent/RS59734B1/en unknown
- 2013-01-23 DK DK13740743T patent/DK2806877T3/en active
- 2013-01-23 SG SG11201503882SA patent/SG11201503882SA/en unknown
- 2013-01-23 LT LT13740743T patent/LT2806877T/en unknown
- 2013-01-23 WO PCT/US2013/022772 patent/WO2013112605A2/en active Application Filing
- 2013-01-23 PL PL13740743T patent/PL2806877T3/en unknown
- 2013-01-23 HU HUE13740743A patent/HUE046800T2/en unknown
- 2013-01-23 ES ES13740743T patent/ES2758446T3/en active Active
- 2013-01-23 US US14/374,080 patent/US20150018327A1/en not_active Abandoned
- 2013-01-23 IL IL286348A patent/IL286348B2/en unknown
-
2014
- 2014-07-22 ZA ZA2014/05401A patent/ZA201405401B/en unknown
- 2014-07-22 IL IL233744A patent/IL233744B/en active IP Right Grant
- 2014-07-23 MX MX2019009739A patent/MX2019009739A/en unknown
- 2014-07-23 MX MX2022010976A patent/MX2022010976A/en unknown
-
2015
- 2015-05-21 HK HK15104869.3A patent/HK1204281A1/en unknown
-
2017
- 2017-07-13 US US15/649,583 patent/US10322139B2/en active Active
- 2017-12-11 JP JP2017236676A patent/JP2018076341A/en active Pending
-
2018
- 2018-02-22 AU AU2018201307A patent/AU2018201307B2/en active Active
-
2019
- 2019-04-26 US US16/396,065 patent/US11426417B2/en active Active
- 2019-12-12 CY CY20191101309T patent/CY1122527T1/en unknown
- 2019-12-30 HR HRP20192348TT patent/HRP20192348T1/en unknown
-
2020
- 2020-05-11 JP JP2020082943A patent/JP2020128409A/en active Pending
- 2020-07-30 IL IL276403A patent/IL276403B/en unknown
- 2020-08-13 AU AU2020217402A patent/AU2020217402B2/en active Active
-
2022
- 2022-04-26 JP JP2022072014A patent/JP7343651B2/en active Active
- 2022-07-20 US US17/869,145 patent/US20230149424A1/en active Pending
-
2023
- 2023-08-31 JP JP2023140708A patent/JP2023162368A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1204281A1 (en) | Neuroactive steroid formulations and methods of treating cns disorders (cns) | |
| IL278396A (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| HK1214832A1 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| HK1206260A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| EP2852388A4 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
| IL241191A0 (en) | Topical compositions and methods of treatment of topical disorders | |
| HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
| IL225239A0 (en) | Compositions for the treatment of acne and related disorders | |
| EP2552433A4 (en) | Compositions and methods for the treatment of somatosensory disorders | |
| HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| EP2696874A4 (en) | Compositions and methods for the treatment of nasal conditions | |
| GB2495885B (en) | Combination pharmaceutical composition and methods of treating genitourinary system disorders | |
| EP2707000A4 (en) | Treatment and management of cns disorders | |
| EP2911660A4 (en) | Compositions and methods for treating estrogen-related medical disorders | |
| EP2912033A4 (en) | Compositions and methods for treating estrogen-related medical disorders | |
| HK1204573A1 (en) | Treatment of inflammatory skin disorders | |
| EP2847158A4 (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| ZA201408045B (en) | Compositions and methods for the treatment of inflammation and lipid disorders | |
| GB201201779D0 (en) | Treatment of inflammatory disorders |